Abstract Androgen receptor (AR) is an attractive target in breast cancer because of its frequent expression in all the molecular subtypes, especially in estrogen receptor (ER)-positive luminal breast cancers. We have previously shown a role for AR overexpression in tamoxifen resistance. We engineered ER-positive MCF-7 cells to overexpress aromatase and AR (MCF-7 AR Arom cells) to explore the role of AR in aromatase inhibitor (AI) resistance. Androstendione (AD) was used as a substrate for aromatization to estrogen. The nonsteroidal AI anastrazole (Ana) inhibited AD-stimulated growth and ER transcriptional activity in MCF-7 Arom cells, but not in MCF-7 AR Arom cells.
Introduction
ER-positive breast cancer is treated with the antiestrogen tamoxifen (Tam) and/or aromatase inhibitors (AIs). Currently, a sequence of an AI followed by Tam significantly reduces the risk recurrence and improves overall patient survival [14] . However, in about 40 % of cases, therapy resistance eventually develops and patients recur with metastatic disease. Multiple mechanisms responsible of resistance exist, including deregulation of the estrogen receptor (ER) pathway itself, alterations in cell cycle and cell survival molecules, and activation of escape pathways that provide tumors with alternative proliferative stimuli [30] . One recognized mechanism of Tam resistance is overexpression (OE) of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) which can be reversed using specific inhibitors [24] .
Using microarray analysis comparing Tam-resistant (Tam R ) metastatic versus Tam-sensitive (Tam  S ) primary breast tumors, we demonstrated that AR levels were relatively higher expressed in the Tam R tumors [8] . Tam was an agonist in AR-overexpressing cells, but the AR antagonist bicalutamide restored sensitivity to Tam [8] . AR is a known clinical target in prostate cancer; however, little is known about its role in breast cancer. The majority of ER-positive breast tumors also express AR, and AR may be a new clinical target in ER-negative tumors [21, 25, 28] . A study comparing transcriptomic differences in early stage hormone receptor-positive breast cancer patients treated with adjuvant Tam who experienced early versus late recurrences, showed increased relative expression of AR in the late recurrence group [22] .
We hypothesize that AR OE confers resistance, and engineered ERa-positive cells to overexpress both AR and aromatase to study the role of AR in response to AIs. We discovered that AR cooperates with ERa in promoting cells to escape the inhibitory effects of the AI anastrazole (Ana), and define potential mechanisms associated with escape from hormone therapy. 
Results

AR overexpression confers resistance to the AI anastrazole (Ana)
Previously, we showed that AR OE drives ERa-positive cells as an escape pathway leading to Tam R [8] . To investigate whether AR OE plays a similar role in escape from AIs, we generated ERa-positive MCF-7 breast cancer cells expressing both AR and aromatase proteins. We made stable transfectants of human aromatase (MCF-7 Arom3 cells, Fig. 1a ). The Arom3 clone was then stably transfected with a full-length AR cDNA (AR Arom5 and Arom10 subclones). Equivalent levels of ERa were detected, indicating that OE of aromatase with or without AR did not significantly affect ERa levels.
We performed growth assays-treating cells with either vehicle (Ctrl) or the AR agonist dihydrotestosterone (DHT). Growth of cells overexpressing AR increased in a dose-dependent manner with DHT (Fig. 1b) . We then explored growth in the presence of the AI Ana using anchorage-dependent (MTT) and independent (soft agar) growth assays (Fig. 1c, d , respectively). As expected with the expression of aromatase in these cells, treatment with the precursor for estrogen (androstendione, AD)-stimulated growth of all cell lines as compared to control (Ctrl) cells. While AD-stimulated growth in Arom3 cells was significantly blocked by Ana, growth of AR-overexpressing cells was not inhibited. Growth stimulation with Ana treatment was seen in some AR-overexpressing cells (Fig. 1c,  Arom10 ). This demonstrates that AD can act as an androgen-stimulating growth, as has been reported [33] . Similar resistance to Ana treatment was obtained using soft agar assays (Fig. 1d) .
Constitutive activation of IGF-1R and downstream phosphorylation of Akt pathway as mechanisms of resistance coincident with AR OE The HER2 family and IGF-1R growth factor receptors are involved in resistance to endocrine therapy in breast cancer [34, 37, 45] . Activation of these growth factor receptor pathways induces rapid non-genomic effects leading to the phosphorylation of the MAPK and PI3K/Akt pathways [6, 44] . To explore effectors of resistance, we treated cells with AD, either alone or in combination with Ana (Fig. 2a) . No differences in the levels of phosphorylated EGFR or HER2 were seen (Supplemental Fig. 1 ). In contrast, high constitutive IGF-1R phosphorylation was detected with AR OE, which was enhanced with AD or Ana treatments. To determine if pIGF-1R activation was involved in resistance to Ana, an IFG-1R inhibitor (Tyrphostin, AG1024) was used (Fig. 2b) . Tyrphostin has been shown to inhibit proliferation in MCF-7 cells [23] . Tyrphostin treatment blocks Akt and Bcl-2 phosphorylation, and up-regulates Bax, p53, and p21 levels [9, 40] . Treatment with this IGF-1R inhibitor alone had little effect on cells, but further decreased the growth of Arom3 cells in combination with AD ? Ana (Fig. 2b) . The IGF-1R inhibitor in combination with AD ? Ana restored sensitivity to Ana in AR-overexpressing cells. Western blot analysis confirmed that AG1024 treatment blocked phosphorylation of IGF-1R and Akt in AR-overexpressing cells (Fig. 2c) .
Constitutively higher pAkt levels were seen with AR OE (Fig. 2d) . AD-stimulated Akt phosphorylation in Arom3 cells, and Ana blocked these effects (Fig. 2d) . Ana treatment of AR-overexpressing cells reduced pAkt levels; however, these levels remained higher with combination treatments. This suggests that AIs were not effective at blocking IGF-1R or downstream Akt activation in ARoverexpressing cells. Next, we looked at the possibility of restoring sensitivity to Ana using an Akt inhibitor (Fig. 2e,  f) . The dual kinase inhibitor Akti 1/2 can block Akt phosphorylation and signaling [5, 17] . Akti 1/2 combined with AD ? Ana drastically reduced Akt phosphorylation levels in AR-overexpressing cells (Fig. 2e) . Treatment with Akti 1/2 alone blocked growth, and combined with Ana restored AI sensitivity in AR-overexpressing cells (Fig. 2f) . Thus, combination therapy with either an IGF-1R or Akt inhibitor may be required for effective AI therapy of AR-overexpressing cells.
AR and ERa functionally collaborate to induce AI R in AR-overexpressing cells AR is often co-expressed along with ERa [20, 26] , and AR and ERa can physically interact and modulate each other's activity [31] . AR levels are important for distribution of AR binding sites and sensitivity to AR agonists [38, 39] . To examine the contribution of AR OE to AI R , we next employed a number of AR antagonists, including bicalutamide (Casodex, Cx) and enzalutamide (MDV3100, MDV). MDV is reported to be more effective than Cx in blocking AR nuclear activity and is effective in castrationresistant prostate cancer [16] . We also tested Zytiga Ò (abiraterone acetate) which works by a different mechanism inhibiting cytochrome P450 (CYP17), the enzyme responsible for the biosynthesis of estrogens and androgens. All three agents are being tested in breast cancer clinical trials. Cells were treated for 9 days with the AR and ER modulators (Fig. 3a) . Tam and the pure steroidal antiestrogen fulvestrant (ICI) significantly reduced growth of all cells. Although AR OE alone conferred resistance to Tam in MCF-7 cells [8] , aromatase OE in these cells rendered them sensitive to Tam inhibition, possibly through enhanced intracellular synthesis of estrogen. As expected, DHT treatment stimulated growth of AR-overexpressing cells, and Cx was inhibitory when used alone. MDV treatment of AR Arom10 cells slightly stimulated growth. Both Cx and MDV treatments blocked DHTstimulated growth in AR-overexpressing cells, demonstrating that AR was indeed stimulatory in these cells. Of the AR antagonists, Abi treatment demonstrated the most efficient inhibition of basal growth in this model system. In combination with AD ? Ana, Abi and ICI treatments effectively blocked growth. This suggests that complete ER blockade, either using an AI plus the ER degrader fulvestrant, or an AI combined with Abi, would be the most effective approach to restore hormone sensitivity in AR-overexpressing cells. Taken together, these data indicate that both AR and ERa signaling collaborate in acquired AI R . To explore AR-transcriptional activity, we performed ARE-luciferase reporter assays in Arom3 cells transiently transfected with increasing amounts of AR plasmid. The AR agonist R1881 stimulated activity (Fig. 3b) . Both E2 and AD-stimulated AR activity in a dose-dependent manner, suggesting a functional interaction between the receptors in inducing AR activity (Fig. 3b) . Ana also stimulated AR activity almost to the same level as E2 (Fig. 3c) . As a Ctrl, Cx treatments blocked R1881 activity.
Ana failed to completely block AD-stimulated AR activity suggesting that AD could function as an androgen and an estrogen. These results suggest that AR activity could be enhanced by estrogens acting through ERa.
ERa activity is insufficiently blocked by Ana in AI R cells AD treatment, but not Ana, stimulated ERa activity, as measured by ERE-luciferase reporter assays (Fig. 4a) . Ana blocked AD-stimulated ER activity in Arom3, but not in either AR-overexpressing cells (Fig. 4a ). This suggests that Ana failed to completely block residual ERa activity which may play a role in AI R . To determine whether AR contributed to AD-stimulated ERa activity, we examined the effects of AR modulators (Fig. 4b) . DHT-stimulated activity in a manner similar to AD alone, and Cx blocked both AD and DHT-stimulated activities. Cx treatment had no effect on ERa activity. These data suggest that both AR and ERa contribute to ER activity in AR-overexpressing cells.
To determine whether the collaboration between AR and ERa in AI R cells involved nuclear interactions, we performed proximity ligation assays (PLA) (Fig. 4c , and Supplementary Fig. 4 ). AR-ERa clusters (red-speckled staining, arrows) were seen in the cytoplasm, but were most prominent in the nucleus of AR Arom5 cells. No staining suggesting limited interactions were observed in Arom3 cells. This demonstrates that AR and ERa are in close proximity and were mainly localized in the nucleus of AI R cells. Next we used ChIP assays to detect AR and ERa associations at the chromatin level on the androgen-regulated PSA enhancer region, and on the classical estrogenregulated pS2 promoter region in AR Arom5 cells (Fig. 4d) . Enrichment of AR on the PSA enhancer region was seen with both AD and DHT treatments. DHT, but not AD, also recruited ERa to the PSA promoter. Since DHT is . AR and ERa enrichment on chromatin was quantified using qPCR and normalized to Ctrl. Data are representative of at least three independent experiments unable to bind ERa, these results suggest that agonistbound AR may recruit ERa to the PSA enhancer region. Similarly, both AD and DHT recruited AR to the pS2 promoter region, whereas only AD but not DHT recruited ERa. This suggests that agonist-occupied AR may recruit ERa to androgen-responsive promoters, and that agonistoccupied AR can be recruited to estrogen-responsive promoter regions.
To explore the subcellular localization of AR and ERa in AI R cells, we utilized confocal microscopy ( Fig. 5a , b, respectively). AR was mainly localized in the cytoplasm in untreated cells with enhanced staining in AR-overexpressing cells. ERa was localized in the nucleus in both cell lines. AR colocalized with ERa in the nucleus after AD treatment and Ana-stimulated AR nuclear localization. Treatment with AD ? Ana enhanced AR-ERa colocalization in the nucleus with some co-staining seen in the cytoplasm (Fig. 5b merge) . These combined results demonstrate that AR and ERa can form complexes in the cytoplasm but predominantly in the nucleus, potentially engaging non-genomic and genomic pathways.
Aromatase is involved in the conversion of androgens into estrogens, and AIs block this activity. In order to identify the most differentially expressed genes in AR Arom-overexpressing cells, we compared gene expression of cells treated with AD and AD ? Ana (Table 1, Table  S1 ); 15.4 % (4.58 ? 10.96 %) of significant differentially expressed genes were known androgen or estrogenresponsive genes. This suggests that either aromatase blockade was incomplete or AR activity contributed to the differentially expressed signature. Aromatase enzyme was shown to be functional in all cells using activity assays (Fig. S2) . These data suggest that both estrogens and androgens contributed to differential gene expression associated with AI R in AR Arom-overexpressing cells.
Tam R ER-positive cells endogenously overexpress AR and are resistant to Ana
We previously reported the establishment of acquired Tam R sublines that were generated by long-term culture of MCF-7 cells under two experimental conditions simulating pre and post-menopausal estrogen levels (TR1 and TR2, respectively) [2, 13, 35] . Figure 6b shows that the two cell lines were indeed resistant to Tam treatment in growth assays in which TR1 and TR2 cells were seeded in the presence of vehicle treatment (ethanol), E2 or Tam. We next questioned whether the acquired Tam R lines expressed aromatase Cyp19, and found that TR2 cells expressed higher levels than TR1 and Arom3 cells (Fig. 6c) . Therefore, we next examined the hormonal responsiveness of TR1 and TR2 cells (Figs. 6d, e) . Treatment with AD-stimulated growth of both cell lines. Ana-stimulated growth, and combined Ana plus AD treatments did not effectively block AD-stimulated growth, like that seen in AR Arom-expressing cells.
However, treatment with Abi alone and in combination blocked cell growth of TR1 and TR2 cells. Thus, data from acquired Tam R cells confirmed our findings that AR OE in ERa-positive cell lines conferred resistance to an AI, and that targeting ERa and AR restored sensitivity to the inhibitor.
Discussion
The optimum care for ERa-positive breast cancers is sequential treatment with Tam and AIs, however, both acquired and de novo resistance to hormone therapy is a major clinical problem in breast cancer. We previously published a role for AR OE in conferring resistance to Tam in breast cancer patients [8] . Herein we report a role for AR in AI R via collaboration with ERa, involving constitutive activation of IGF-1R and AKT signaling pathways.
In prostate cancer, AR has been extensively studied and its role as a critical effector of tumor development and progression is well documented, therefore, AR antagonists are effective for the treatment of advanced prostate cancer [1] . In breast cancer, the role of AR is complex because androgens can stimulate or inhibit cell growth [4, 7, 8, 18, 19, 22, 25, 28, 32] . Because of the dual actions of androgens in breast cancer, it is very important to identify biomarkers of AR activity to manage patients in AR-targeted studies, like the use of PSA monitoring in prostate cancer. An AR-targeted trial using bicalutamide has been recently reported in AR-positive, ER-negative breast cancer patients demonstrating proof-of-principle clinical benefit in metastatic breast cancer [15] , and a Phase II clinical trial with enzalutamide (MDV3100) has also recently opened in ERpositive, HER2 normal breast cancer patients [43] . A study exploring whether abiraterone acetate can extend clinical benefit with an AI is planned to be completed in July 2014 (NCT01381874). Our results suggest that AR OE may be a novel determinant of resistance to AIs in breast cancer. Here we show that overexpressing AR in ERa-positive MCF-7BK cells rendered them refractory to Ana. In this model, Ana alone stimulated anchorage-independent growth assays. This effect could be due to the known increase in androgens with Ana treatment [11] .
Resistance to hormonal therapy is often due to the emergence of escape survival pathways [27, 30, 41] . In ERa-positive AR-overexpressing cells, IGF-1R was constitutively activated along with downstream activation of pAkt. Mechanisms of escape in our AR-overexpressing model are unique in that we did not observe activation of the HER growth factor receptor family, which is the dominant escape pathway in other models of hormone resistance. Furthermore, IGF-1R or Akt inhibitors were very effective in restoring Ana sensitivity. Clinically, this suggests that pIGF-1R and/or pAkt may be biomarkers of resistance associated with AR OE. Of course this will need to be tested in prospective clinical studies. We do not yet understand mechanistically how AR OE leads to constitutive activation of pIGF-1R, but potentially this could include activation of this pathway at several levels as we observed in another model of AI resistance due to a specific somatic mutation in ESR1 (K303R ERa) [3, 10] . Blocking AR with any of the AR modulators or synthesis inhibitors tested (bicalutamide, enzalutamide, or abiraterone) effectively restored hormone sensitivity in AR-overexpressing cells. The involvement of both AR and ERa in resistance was evident when AR activity was blocked with ERa antagonists, and similarly ER transcriptional activity was affected by AR antagonists, suggesting cooperation between the two steroid receptors. Ana treatment failed to completely block residual ERa activity in AR-overexpressing cells, suggesting that the failure to block estrogen-stimulated activity could define AI R . Thus, we conclude that both AR and ERa functionally cooperate and contribute to enhanced residual ERa activity in resistant cells.
Immunocytochemistry and PLA assays demonstrated collaboration between AR and ERa at the nuclear level. PLA data suggested that AR and ERa may be in close proximity in the nucleus. ChIP assays also confirmed these findings demonstrating that AR and ERa cooperate on known androgen and estrogen-responsive gene promoters. Collectively this suggests that agonist-occupied AR may recruit, either directly or indirectly, ERa to androgenresponsive promoters, and that AR can also be recruited to estrogen-responsive promoter regions. We also demonstrated that ER-positive breast cancer cells up-regulate endogenous AR with long-term Tam treatment (TR1 and TR2), and growth of these cells was effectively blocked with Abi treatment. This is consistent with a role for both AR and ERa in the resistant phenotype, and provides confirmation of the role of AR in resistance using cells with endogenous increases in AR.
An important clinically relevant finding is that resistance was associated with an increase in androgen and estrogenresponsive gene expression, and that AI R may be associated with a failure to completely block AR-and/or ERregulated gene expression. Our preclinical data suggest that simultaneous and complete blockade of AR and ER-regulated escape survival pathways may be required to provide clinical benefit. Thus, we predict that AR OE is an important marker of resistance to both Tam and AIs in patients with ER-positive breast cancer, depending on the expression of aromatase in the microenvironment and/or intratumoral aromatase levels. Targeting AR signaling, which can impact on ERa function, may provide a unique strategy for more effective treatment of ER-positive breast cancer, or a longer extension of clinical benefit from ERtargeted therapy in metastatic patients. With the rapid expansion of new AR-targeted agents in the cancer armamentarium, this is an exciting possibility in targeted breast cancer therapy.
Materials and methods
Reagents, hormones, and antibodies
Methyltrienolone (R1881), 17b-estradiol (E2), and androstenedione (AD) were obtained from Sigma (St. Louis, MO). Anastrazole (Arimidex, Ana) was obtained from AstraZeneca (London, UK), and bicalutamide (Casodex Ò , Cx) was purchased from LKT Laboratories Inc. (St. Paul, MN). Abiraterone acetate was a kind gift from Janssen Pharmaceuticals (Beerse, Belgium). Antibodies used for immunoblotting were anti-GAPDH from Santa Cruz Biotechnology (Santa Cruz, CA), anti-ERa 6F11 from Vector Laboratories Inc. (Burlingame, CA), anti-PR from DAKO (Carpinteria, CA), anti-total and phosphorylated IRS-1, HER2, IGF-1R, AKT, and MAPK from Cell Signaling Technology (Beverly, MA), anti-AR clone 441 from Santa Cruz Biotechnology, and anti-aromatase (CYP19) from Serotec (Oxford, UK). MTT (Thiazoyl blue tetrazolium bromide) was obtained from Sigma.
Cells and stable transfection MCF-7BK cells have been maintained in our laboratory for over 20 years. Cells were grown in MEM (Invitrogen, Carlsbad, CA) supplemented with 10 % fetal bovine serum (FBS; Summit Biotechnology, Fort Collins, CO), 200 units/ ml penicillin, 200 lg/ml streptomycin, and 10 lg/ml insulin. Cells were incubated at 37°C in 5 % CO 2 . To generate MCF-7 cells stably overexpressing the CYP19 aromatase enzyme (designated Arom cells), pCR3.1-CYP19 cDNA, or empty pCR3.1 vector (Invitrogen) were transfected as described in [4] , and positive clones were identified using immunoblot analysis with the anti-CYP19 antibody. To generate MCF-7BK cells that stably overexpress aromatase and AR, we transfected Arom cells as described above, and clones were identified using immunoblot analysis with the anti-AR antibody clone 441.
Cell extraction and immunoblot analysis
Cells were starved in phenol red-and serum-free MEM for 48 h, and then treated for 24-48 h with different compounds as indicated. For rapid signaling studies, cells were starved as above followed by 20 min treatments with vehicle (C, ethanol or DMSO), estrogen (E2, 10 nM), AD (10 nM), Ana (1 lM), R1881 (10 nM), or bicalutamide (Cx, 10 lM). After these varying treatments, cells were rinsed twice with ice cold phosphate-buffered saline (PBS) and were then lysed immediately with 200lL of cell lysis buffer (20 mM Tris-HCl, pH 7.4, 15 mM NaCl, 1 mM bglycerophosphate, 1 mM sodium orthovanadate, and 10 % glycerol) plus 1:100 proteinase inhibitor cocktail III (Calbiochem, La Jolla, CA) per 100 mm tissue culture plate. Cell lysates were cleared by centrifugation at 16,0009g for 10 min at 4°C. Protein concentrations were determined using the BCA Protein Assay kit (Pierce, Rockford, IL) according to the manufacturer's directions. Equal amounts of cell extracts were resolved under denaturing conditions by electrophoresis in 8-10 % polyacrylamide gels containing SDS (SDS-PAGE) and transferred to nitrocellulose membranes by electroblotting (Protran Ò Nitrocellulose Membranes, GE Healthcare, Piscataway, NJ). The blots were first stained with Ponceau S to confirm uniform transfer of all samples. After blocking of the transferred nitrocellulose membranes, they were incubated with primary antibodies overnight at 4°C, incubated with secondary antibodies for 1 h at room temperature, and developed with enhanced chemiluminescence reagents (ProteinSimple, San Jose, CA).
Anchorage-independent growth assays Cells were starved for 2 days in phenol red and serum-free MEM supplemented with 5 % charcoal-stripped FBS, and 200 lg/ml streptomycin. Soft agar assays were performed in six-well plates using 5 9 10 3 cells per well. After 14 days, the colonies with greater than 50 cells from triplicate assays were counted. Data shown are the mean colony numbers of three wells, and are representative of two independent experiments.
Aromatase activity assays
Aromatase activity in medium from subconfluent cell cultures was measured by a tritiated water release assay using 0.5 lM [1b-
3 H]androst-4-ene-3,17-dione (PerkinElmer Life Sciences) as substrate. Incubations were performed at 37°C for 2 h under a 95:5 % air/CO 2 atmosphere. Results obtained were expressed as picomoles/h and normalized to milligrams of protein (picomoles/h/mg of protein).
Transient transfection assay and ERE-luciferase reporter gene assays MCF-7BK, Arom, and AR Arom cells were serum-starved using phenol red and serum-free MEM containing 5 % charcoal-stripped serum for 48 h, then plated in 24-well plates (7 9 10 4 cells per well). After incubation overnight at 37°C, cells were co-transfected with a plasmid containing an estrogen-responsive element (ERE) linked to luciferase (ERE-Luc, 0.25 lg per well), and a plasmid expressing b-galactosidase (b -gal, 0.1 lg/well) to normalize transfection efficiency through the whole assay. Lipofectamin TM LTX with Plus TM reagent (Invitrogen) was used following the manufacturer's instructions. Eight hours after transfection, cells were treated with the indicated ligands for 16-24 h, then lysed and the luciferase assay was performed using a luciferase reporter assay kit (Promega). b-galactosidase activity was used to normalize the transfection efficiencies. Transfections were performed in triplicate.
MTT assays MCF-7BK, Arom, and AR Arom cells were plated in 96-well plates, then serum-starved as described above for 48 h. Cells were treated with the indicated ligands for 7 days then MTT (Thiazoyl blue tetrazolium bromide) solution (5 g/L) was added to each well, and plates were re-incubated for 4 h. The violet precipitate (formazan) that appears during incubation, proportional to the number of living cells, was solubilized using DMSO and the optical density (OD) of the violet solution was measured using a colorimeter. The OD values (570-650 nm) were normalized using the ODs obtained on at the day of treatment. Each condition of treatment was performed at least in triplicate.
Immunofluorescence
For immunocytochemical staining, cells were grown on coverslips in full media then serum-starved using charcoalstripped media for 48 h. Cells were fixed in 4 % paraformaldehyde in PBS buffer for 10 min at room temperature. After fixation, cells were washed 3 times with PBS then permeabilized using a detergent solution (0.2 %Triton X-100, 0.2 % BSA prepared in PBS) for 10 min at room temperature, washed 39 with PBS, and incubated in blocking solution (1 % BSA) for 30 min at room temperature. Incubation of primary antibodies diluted in blocking buffer was carried out overnight at 4°C. We used anti-ERa (1/20) and anti-AR (1/100) antibodies. Coverslips were washed three times in PBS. Cells were then incubated with an Alexa 488-conjugated goat-anti-mouse (1:200) (Molecular Probes, Eugene, OR) and an Alexa 546-conjugated goat-anti-rabbit (1:500) (Molecular Probes, Eugene, OR). Nuclei were stained for 5 min with DAPI (10 lg/ml) (Vectashield Ò , Vector laboratories). Immunofluorescence microscopy was performed using a Leica confocal microscope TCS SP5 (Leica Microsystems, Buffalo Grove, IL) and LAS software to collect images.
Proximity ligation assays (PLA)
PLA was performed using the Duolink kit according to manufacturer's instructions (Olink Bioscience, Uppsala, Sweden). Briefly, cells were plated and treated with indicated hormones in chamber slides. After fixation with 4 % paraformaldehyde, cells were permeabilized and non-specific binding sites blocked with 1 % bovine serum albumin solution (BSA). Samples were then incubated with specific primary antibodies AR rabbit antibody D6F11 (Cell Signaling), and ERa clone 6F11 (Vector Laboratories). Samples were incubated with secondary antibodies linked to PLA probes. Next, a ligase was added to the mixture allowing formation of complete circularized oligonucleotides from the juxtaposed probes. Finally, Detection Reagent Red was added to the mixture to recognize the amplified DNA sequences and allow visualization under microscope of AR-ERa complexes. Sequential washings with PBS were performed after each step.
Immunoprecipitation (IP)
Dynabeads
Ò Protein A and a Protein G kit (Invitrogen, Carlsbad, CA) were used following manufacturer's instructions. Briefly, 10 lg of antibody was incubated with 50 lL of a 1:1 Protein A:Protein G Dynabeads Ò mixture. 200 lg of protein was then added to the complex beads plus antibody and rotated for 15 min at room temperature. After washing, mixture was resuspended in SDS sample buffer and boiled for 7 min to dissociate the immunocomplex from the beads. The supernatant was then collected and subjected to Western blot analysis.
Quantitative Chromatin IP (ChIP)
Rabbit polyclonal AR N-20 and ERa HC-20 (Santa Cruz Biotechnology) antibodies were used for ChIP. Dynabeads Ò Protein A and Protein G kit (Invitrogen) were used. Cells plated at 80 % confluence were subjected to different treatments (Ctrl, AD or DHT) for 90 min. Protein-Chromatin crosslinking was performed using 37 % formaldehyde solution for 10 min then quenched with Glycine (0.375 M). Cells were then lysed and subjected to 4 sonication steps to shear chromatin to an average length of about 500-1000 bp. Cell debris was removed after centrifugation and the supernatant diluted 109 with ChIP dilution buffer. The input fraction was set aside at this step (150 lL), the remaining lysate was split into 2 equal aliquots (one for each antibody) and incubated overnight at 4°C in the presence of 10 lg of antibody. The next day, samples were incubated with 50 lL of precleared Dynabeads mixture for 2 h at 4°C with rotation. Samples were then washed sequentially with low salt immune bufferhigh salt immune buffer-TE buffer. To collect DNA-protein complexes, beads were extracted 3 times with 50 lL of elution buffer. To reverse crosslinking, a solution of NaHCO3 was added to all samples, and incubated for 6 h at 65°C. Immunoprecipitated DNA was purified using Qiaex II gel extraction Kit (Qiagen, Valencia, CA) following manufacturer's instructions. Fold enrichment of nuclear receptors at promoter regions in Ctrl samples versus treated samples was calculated by DDCT using quantitative PCR (Applied Biosystems 7500 Fast Real-Time PCR instrument). Specific promoter regions assayed were pS2 (Cell Signaling) and the PSA enhancer region (Applied Biosystems, Foster City, CA).
Microarray analyses
For microarray analyses, vector Ctrl and AR-overexpressing cells were cultured in 5 % CSM for 48 h, and then cells were treated overnight with Ana with or without AD. After 39 PBS washes, cells were pelleted and RNA was extracted using RNeasy micro kit (Qiagen) following manufacturer's instructions. Labeled cRNA was hybridized onto Affymetrix GeneChip Human Genome U133 Plus 2.0 Arrays (Affymetrix Inc. Santa Clara, CA). Three chips per group were used. Chips were normalized with probesetlevel estimates of expression previously generated using tools in Bioconductor (www.bioconductor.org) and/or BRB Array tools (http://linus.nci.nih.gov/BRB-Array Tools.html) [12] . Analyses employed a 'moderated' linear model [36] , and contrasts to detect changes with treatment (Ana, Ana ? AD) that differ between vector Ctrl and AR OE lines. Analyses focused on the overlap of gene expression associated with treatments between sensitive and resistant cell line models using meta-analytic methods [29, 42] .
Statistics
Experimental data were analyzed for statistical significance using a two-tailed Student's t test or one-way ANOVA test, and p-value was corrected for multiple comparisons.
